New targeted treatment approved.

10 AprNew targeted treatment approved.

Written by PCaSO DPO
Categorised News

Olaparib is a drug with the potential to extend the lives of hundreds of prostate cancer patients, specifically those men with the BRCA gene mutation who have stopped responding to abiraterone. NICE have now approved this for use on the NHS, in what is seen as an important precedent for the use of targeted treatment of this kind. Credit: prostatecanceruk.org

More Latest News Articles

New Video – Dr. Caroline Manetta – Radiotherapy Procedures and SABR
Video – Dr. Caroline Manetta Radiotherapy Procedures and SABR. In this video Dr. Manetta discussed updates ...
PCUK TRANSFORM Screening Trial Announced
PCUK Research activity
Prostate Cancer UK as a National Charity are currently funding four separate University research programmes, ...
Knowledge Empowers October 2023 edition now available
The latest fully revised, updated and reformatted version of Knowledge Empowers is now available to ...
Bill Turnbull and YOUR diagnosis
Prostate Cancer UK are keen to hear patient stories from men whose diagnosis was spurred ...
“What on Earth is a prostate?”
Watch this 2.5 minute video from PCUK, highlighting the mixed levels of public knowledge about ...
Hormone Therapy – patient survey
A new survey is looking at hormone therapy patient experiences, to help gather evidence for ...
AI and PCa?
Prostate Cancer report that funding has been granted for research into whether Artificial Intelligence could ...
1st. June Zoom Presentation by Dr. Angus Robinson
Our own medical advisor, Dr Angus Robinson, Consultant Clinical Oncologist, Sussex Cancer Centre, Urology and ...
Hove PSA Testing event a success
PCaSO’s PSA event at Hove on 1st April saw 273 men attend for the blood ...
Working to block metastatic spread
Prostate Cancer Research are funding a project to help identify drugs that could block prostate ...
New blood test could help catch prostate cancer early
Swansea University have received a grant of £400,000 to research a potential new blood test ...